Back to News
Market Impact: 0.2
Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Source: prnewswire.com
Legal & LitigationHealthcare & Biotech
Hagens Berman Sobol Shapiro notified investors in Aardvark Therapeutics (NASDAQ: AARD) of a pending securities class-action lawsuit. The notice creates a legal overhang for the biotech company, although the article provides no allegations, damages, financial impact, or case timing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.35
Ticker Sentiment
AARD-0.80
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Thousands of Israelis rally against Netanyahu gov’t days before election
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective